Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258

Vincerx Pharma (VINC) and Oqory highlighted Phase 1a/1b data for Oqory’s anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided insights into their proposed strategic merger, which aims to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline by leveraging their combined expertise. Recent data highlights, including those presented at the 2024 European Society for Medical Oncology, include: Evaluable patients with previously untreated TNBC: As presented at ESMO, the confirmed overall response rate was 76% and disease control rate was 100%. Median duration of response and progression-free survival had not yet been reached. A recent data cut from January 2025, with ten additional patients evaluable for efficacy, showed an improved confirmed ORR of 80%, with median DOR and PFS still not reached. Evaluable patients with late-stage TNBC: As presented at ESMO, the confirmed ORR was 27% and DCR was 62%, with 6-month DOR and PFS rates of 39% and 25%, respectively. Evaluable patients with HR+/HER2- breast cancer: As presented at ESMO, the confirmed ORR was 39%, DCR was 78%, and 6-month DOR and PFS rates of 70% and 55%, respectively, with a median PFS of 7.4 months.